Drugs.com Clinical Trial ResultsOriginal article
Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
Data ReadoutpositiveivonescimabPositive
AI Analysis
Summary
Summit Therapeutics announced publication of primary analysis results from the global Phase III HARMONi trial of ivonescimab plus chemotherapy in The Lancet Oncology. The positive trial results represent a significant milestone for the cancer treatment program.
Clinical Trial Data
Phase
Phase III
Primary Endpoint
Met
Outcome Details
Primary analysis results from global Phase III HARMONi trial published in The Lancet Oncology
Importance:7/10
Sentiment:
0.70
Phase IIIData PublicationOncologyImmunotherapy
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on August 25, 2026 3:08 AM